Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy

被引：3

作者：

Handunnetti, Sasanka ^{[1
,2
,3
]}

Anderson, Mary Ann ^{[1
,2
,4
]}

Roberts, Andrew W. ^{[1
,2
,3
,4
]}

Davids, Matthew S. ^{[5
]}

Ma, Shuo ^{[6
]}

Boyer, Michelle ^{[7
]}

Arzt, Jennifer ^{[8
]}

Al Masud, Abdullah ^{[8
]}

Popovic, Relja ^{[8
]}

Jacobson, Amanda ^{[8
]}

Kim, Su Y. ^{[8
]}

Seymour, John F. ^{[1
,2
,4
]}

机构：

[1] Peter MacCallum Canc Ctr, Clin Haematol Dept, 305 Grattan St, Melbourne, Vic, Australia

[2] Royal Melbourne Hosp, 305 Grattan St, Melbourne, Vic, Australia

[3] Univ Melbourne, Fac Med Dent & Hlth Sci, Melbourne, Vic, Australia

[4] Walter & Eliza Hall Inst Med Res, Div Blood Cells & Blood Canc, Parkville, Vic, Australia

[5] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[6] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA

[7] F Hoffmann La Roche Ltd, Welwyn Garden City, England

[8] AbbVie Inc, N Chicago, IL USA

来源：

EJHAEM | 2021年 / 2卷 / 02期

关键词：

chronic lymphocytic leukemia; relapsed/refractory; rituximab; small lymphocytic lymphoma; venetoclax; CLL; OBINUTUZUMAB; DIAGNOSIS; BCL2;

D O I：

10.1002/jha2.177

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Venetoclax is approved as monotherapy and in combination with rituximab for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Two Phase 1 studies (M12-175 [NCT01328626]; M13-365 [NCT01682616]) were conducted in which patients who initially responded and then progressed on venetoclax monotherapy could receive added rituximab. Ten patients were evaluated (M12-175, n = 8; M13-365, n = 2), and five (50%) responded again upon addition of rituximab, including three complete and two partial responses. Responses were ongoing after 5-10 months of follow-up. Addition of rituximab was well tolerated. These findings indicate potential clinical benefit with rituximab added to venetoclax post-progression in some patients with R/R CLL.

引用

页码：266 / 271

页数：6

共 17 条

[1] Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax
Anderson, Mary Ann
Tam, Constantine
Lew, Thomas E.
Juneja, Surender
Juneja, Manu
Westerman, David
Wall, Meaghan
Lade, Stephen
Gorelik, Alexandra
Huang, David C. S.
Seymour, John F.
Roberts, Andrew W.
[J]. BLOOD, 2017, 129 (25) : 3362 - 3370
[2] Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
Blombery, Piers
Anderson, Mary Ann
Gong, Jia-nan
Thijssen, Rachel
Birkinshaw, Richard W.
Thompson, Ella R.
Teh, Charis E.
Nguyen, Tamia
Xu, Zhen
Flensburg, Christoffer
Lew, Thomas E.
Majewski, Ian J.
Gray, Daniel H. D.
Westerman, David A.
Tam, Constantine S.
Seymour, John F.
Czabotar, Peter E.
Huang, David C. S.
Roberts, Andrew W.
[J]. CANCER DISCOVERY, 2019, 9 (03) : 342 - 353
[3] Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era
Butler, L. A.
Tam, C. S.
Seymour, J. F.
[J]. BLOOD REVIEWS, 2017, 31 (05) : 318 - 327
[4] Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
Fischer, K.
Al-Sawaf, O.
Bahlo, J.
Fink, A. -M.
Tandon, M.
Dixon, M.
Robrecht, S.
Warburton, S.
Humphrey, K.
Samoylova, O.
Liberati, A. M.
Pinilla-Ibarz, J.
Opat, S.
Sivcheva, L.
Du, K. Le
Fogliatto, L. M.
Niemann, C. U.
Weinkove, R.
Robinson, S.
Kipps, T. J.
Boettcher, S.
Tausch, E.
Humerickhouse, R.
Eichhorst, B.
Wendtner, C. -M.
Langerak, A. W.
Kreuzer, K. -A.
Ritgen, M.
Goede, V.
Stilgenbauer, S.
Mobasher, M.
Hallek, M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (23) : 2225 - 2236
[5] Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Goede, Valentin
Fischer, Kirsten
Busch, Raymonde
Engelke, Anja
Eichhorst, Barbara
Wendtner, Clemens M.
Chagorova, Tatiana
de la Serna, Javier
Dilhuydy, Marie-Sarah
Illmer, Thomas
Opat, Stephen
Owen, Carolyn J.
Samoylova, Olga
Kreuzer, Karl-Anton
Stilgenbauer, Stephan
Doehner, Hartmut
Langerak, Anton W.
Ritgen, Matthias
Kneba, Michael
Asikanius, Elina
Humphrey, Kathryn
Wenger, Michael
Hallek, Michael
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (12) : 1101 - 1110
[6] Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Hallek, Michael
Cheson, Bruce D.
Catovsky, Daniel
Caligaris-Cappio, Federico
Dighiero, Guillaume
Doehner, Hartmut
Hillmen, Peter
Keating, Michael J.
Montserrat, Emili
Rai, Kanti R.
Kipps, Thomas J.
[J]. BLOOD, 2008, 111 (12) : 5446 - 5456
[7] Ibrutinib and Venetoclax for First-Line Treatment of CLL
Jain, Nitin
Keating, Michael
Thompson, Philip
Ferrajoli, Alessandra
Burger, Jan
Borthakur, Gautam
Takahashi, Koichi
Estrov, Zeev
Fowler, Nathan
Kadia, Tapan
Konopleva, Marina
Alvarado, Yesid
Yilmaz, Musa
DiNardo, Courtney
Bose, Prithviraj
Ohanian, Maro
Pemmaraju, Naveen
Jabbour, Elias
Sasaki, Koji
Kanagal-Shamanna, Rashmi
Patel, Keyur
Jorgensen, Jeffrey
Garg, Naveen
Wang, Xuemei
Sondermann, Katrina
Cruz, Nichole
Wei, Chongjuan
Ayala, Ana
Plunkett, William
Kantarjian, Hagop
Gandhi, Varsha
Wierda, William
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (22) : 2095 - 2103
[8] Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)
Kater, Arnon P.
Kipps, Thomas J.
Eichhorst, Barbara
Hillmen, Peter
D'Rozario, James
Owen, Carolyn
Assouline, Sarit E.
Lamanna, Nicole
Robak, Tadeusz J.
de la Serna, Javier
Jaeger, Ulrich
Cartron, Guillaume
Montillo, Marco
Mellink, Clemens
Chyla, Brenda J.
Wilson, Cameron
Wu, Jenny
Jiang, Yanwen
Lefebure, Marcus
Boyer, Michelle
Seymour, John F.
[J]. BLOOD, 2020, 136
[9] BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax
Lin, Victor S.
Lew, Thomas E.
Handunnetti, Sasanka M.
Blombery, Piers
Nguyen, Tamia
Westerman, David A.
Kuss, Bryone J.
Tam, Constantine S.
Roberts, Andrew W.
Seymour, John F.
Anderson, Mary Ann
[J]. BLOOD, 2020, 135 (25) : 2266 - 2270
[10] Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy
Mato, Anthony R.
Roeker, Lindsey E.
Jacobs, Ryan
Hill, Brian T.
Lamanna, Nicole
Brander, Danielle
Shadman, Mazyar
Ujjani, Chaitra S.
Yazdy, Maryam Sarraf
Perini, Guilherme Fleury
Pinilla-Ibarz, Javier A.
Barrientos, Jacqueline
Skarbnik, Alan P.
Torka, Pallawi
Pu, Jeffrey J.
Pagel, John M.
Gohil, Satyen
Fakhri, Bita
Choi, Michael
Coombs, Catherine C.
Rhodes, Joanna
Barr, Paul M.
Portell, Craig A.
Parry, Helen
Garcia, Christine A.
Whitaker, Kate J.
Winter, Allison M.
Sitlinger, Andrea
Khajavian, Sirin
Grajales-Cruz, Ariel F.
Isaac, Krista M.
Shah, Pratik
Akhtar, Othman S.
Pocock, Rachael
Lam, Kentson
Voorhees, Timothy J.
Schuster, Stephen J.
Rodgers, Thomas D.
Fox, Christopher P.
Martinez-Calle, Nicolas
Munir, Talha
Bhavsar, Erica B.
Bailey, Neil
Lee, Jason C.
Weissbrot, Hanna B.
Nabhan, Chadi
Goodfriend, Julie M.
King, Amber C.
Zelenetz, Andrew D.
Dorsey, Colleen
[J]. CLINICAL CANCER RESEARCH, 2020, 26 (14) : 3589 - 3596

← 1 2 →